Physician profile
David Husted
NPI 1255370235
$8,889.29
in general payments reported to CMS, 2019-2025
22 companies · $2,078 in 2025
The $2,078 reported for 2025 was more than what 89% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16.93 · 2020: $19.22 · 2021: $20.67 · 2022: $2,641 · 2023: $1,651 · 2024: $2,462 · 2025: $2,078.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,192.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,191.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Brainsway USA INC | $1,663.00 | 2022 | |
| Abbvie INC. | $1,339.11 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $1,008.17 | 2022-2025 | Spravato, Invega Sustenna |
| Neurocrine Biosciences, INC. | $918.87 | 2019-2025 | Ingrezza |
| Alkermes, INC. | $468.60 | 2022-2025 | Lybalvi, Aristada |
| Livanova USA, INC. | $414.29 | 2023-2025 | Vns Therapy Symmetry Model 8103 Generator |
| Corium, LLC | $395.90 | 2023-2025 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $359.66 | 2023-2025 | Rexulti, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $331.01 | 2022-2025 | Austedo Xr, Austedo Xr, Austedo |
| Axsome Therapeutics, INC. | $329.75 | 2023-2025 | Auvelity, Sunosi |
| E.R. Squibb & Sons, L.L.C. | $294.79 | 2024-2025 | Cobenfy |
| Lundbeck LLC | $284.44 | 2023-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $280.27 | 2022-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $207.12 | 2022-2024 | Trintellix |
| Idorsia Pharmaceuticals US INC | $150.56 | 2022-2024 | Quviviq |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $144.73 | 2022-2024 | Loreev Xr, Sertraline Hcl, Gralise |
| Vanda Pharmaceuticals INC. | $97.78 | 2025 | Fanapt |
| Supernus Pharmaceuticals, INC. | $92.78 | 2022-2024 | Qelbree, Qelbree |
| Ironshore Pharmaceuticals INC. | $34.28 | 2024 | |
| Vertex Pharmaceuticals Incorporated | $29.40 | 2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $22.74 | 2025 | Rejoyn |
| Neos Therapeutics, Lp | $22.04 | 2024 | Adzenys Xr-Odt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Husted listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.